[Department of Error] Department of Error
Moskowitz CH, Nademanee A, Masszi T, et al, for the AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853–62—In this Article, the colours of the curves in figure 2C were reversed. This correction has been made to the online version as of Aug 7, 2015.